

Technology Appraisal Committee Meeting (Committee A)
10 Spring Gardens, London SW1A 2BU

Minutes: Confirmed

Date and Time: Thursday 19 July 2018, 10:00 – 17:00

Present:		
1.	Dr Jane Adam (Chair)	Present for all notes
2.	Professor Iain Squire (Vice-Chair)	Present for all notes
3.	Dr Justin Daniels	Present for notes 1 to 11
4.	Dr Steve Edwards	Present for all notes
5.	Dr Rita Faria	Present for all notes
6.	Mr Adrian Griffin	Present for all notes
7.	Mrs Sarah Parry	Present for all notes
8.	Ms Pamela Rees	Present for all notes
9.	Dr Paul Robinson	Present for notes 1 to 6
10.	Mr Stephen Sharp	Present for all notes
11.	Dr Mohit Sharma	Present for all notes
12.	Dr Brian Shine	Present for all notes
13.	Dr John Watkins	Present for all notes
14.	Professor Olivia Wu	Present for all notes

In attendance:

Helen Knight	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Janet Robertson	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Thomas Feist	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Gavin Kenny	Assistant Project Manager, National Institute for Health and Care Excellence	Present for all notes
Boglarka Mikudina	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 6
Joanna Richardson	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 1 to 6

Sana Khan	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 7 to 11
Zoe Charles	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 7 to 11
Juliet Kenny	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 12 to 16
Eleanor Donegan	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 12 to 16
Daniel Pollard	ScHARR, Evidence Review Group	Present for notes 1 to 3
Sarah Davis	ScHARR, Evidence Review Group	Present for notes 1 to 3
Ewen Cummins	Warwick Evidence, Evidence Review Group	Present for notes 7 to 8
Martin Connock	Warwick Evidence, Evidence Review Group	Present for notes 7 to 8
Lena Alkhudairy	Warwick Evidence, Evidence Review Group	Present for notes 7 to 8
Chidozie Nduka	Warwick Evidence, Evidence Review Group	Present for notes 12 to 13
Xavier Armoiry	Warwick Evidence, Evidence Review Group	Present for notes 12 to 13
Professor Tariq Iqbal	Clinical expert	Present for notes 1 to 3
Janindra Warusavitarne	Clinical expert	Present for notes 1 to 3
Avinash Gupta	Clinical expert	Present for notes 7 to 8
Paul Nathan	Clinical expert	Present for notes 7 to 8
Professor Jayant Vaidya	Clinical expert	Present for notes 12 to 13
Professor Andrew Wardley	Clinical expert	Present for notes 12 to 13
Paula Carr	Patient expert	Present for notes 1 to 3
Damien McCluskey	Patient expert	Present for notes 1 to 3

Delia Sworm	Patient expert	Present for notes 7 to 8x
Melanie Sturtevant	Patient expert	Present for notes 12 to 13
Professor Peter Clark	Cancer Drugs Fund Clinical Lead	Present for notes 7 to 16

Non-public attendees:

Ana Uribe Echeverry	Corporate Office Coordinator, NICE	Present for all notes
Adam Storrow	Business Analyst, NICE	Present for all notes
Ria Skelton	Editor, NICE	Present for all notes
Gemma Barnacle	Project Manager, NICE	Present for all notes
Archik Das	Warwick Evidence	Present for notes 7 to 8
Felix Archana	Warwick Evidence	Present for notes 7 to 8
Abby Scott	NIHRI	Present for notes 1 to 11
Jenny Williams	NIHRI	Present for notes 1 to 11
Hamish Lunagaria	Scientific Advice, NICE	Present for notes 1 to 6
Heather Stegenga	Scientific Advice, NICE	Present for notes 1 to 6

Notes

Any other business

1. None.

Appraisal of darvadstrocel for treating perianal fistula in Crohn's disease [ID960]

Part 1 – Open session

2. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Takeda.
3. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests.
 - 3.1. Mr Janindra Warusavitarne declared a personal specific financial interest as he has received speaker fees from Takeda on an unrelated topic and was an adviser to the ERG for this appraisal.
 - 3.1.1. It was agreed that this declaration would not prevent them from participating in this section of the meeting.
 - 3.2. No further conflicts of interest were declared for this appraisal.

Part 2 – Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting)

4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
5. The committee decision was based on consensus.
6. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of dabrafenib in combination with trametinib for adjuvant treatment of resected BRAF V600 positive malignant melanoma [ID1226]

Part 1 – Open session

7. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Novartis.

8. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests
 - 8.1. Dr Avinash Gupta declared a direct financial interest as he has been paid fees for speaking at Novartis sponsored educational events. The fees were paid to an educational fund at the Christie Hospital.
 - 8.1.1. It was agreed that this declaration would not prevent them from participating in this section of the meeting.
 - 8.2. Dr Paul Nathan declared a direct financial interest as he is an advisory board member for Novartis, BMS, Roche, AstraZeneca, Pfizer, Immunocore and Pierre-Fabre. He was also an expert witness to the EMA for this treatment.
 - 8.2.1. It was agreed that this declaration would not prevent them from participating in this section of the meeting.
 - 8.3. Professor Iain Squire declared an indirect interest as he has received consultancy fees by Novartis relating to a different disease area.
 - 8.3.1. It was agreed that this declaration would not prevent them from participating in this section of the meeting.
- 8.4. No further conflicts of interest were declared for this appraisal.

Part 2 – Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting)

9. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
10. The committee decision was based on consensus.
11. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of pertuzumab for adjuvant treatment of early HER2-positive breast cancer [ID1192]

Part 1 – Open session

12. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Roche.

13. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests

13.1. Professor Andrew Wardley declared a direct financial interest as he has been paid by Roche for advisory work and speaker meetings. He is also the lead for development of a primary medical therapy trial in HER-2 positive breast cancer for NCRI breast cancer clinical studies group.

13.1.1. It was agreed that this declaration would not prevent them from participating in this section of the meeting.

13.2. Melanie Sturtevant declared an indirect interest as her organisation receives funding from the pharmaceutical industry. This is independent of their work on access to drugs.

13.2.1. It was agreed that this declaration would not prevent them from participating in this section of the meeting.

13.3. No further conflicts of interest were declared for this appraisal.

Part 2 – Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting)

14. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.

15. The committee decision was based on consensus.

16. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.